- Home
- IOBT
IOBT
IO Biotech Inc.
as 09-09-2024 4:00pm EST
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
| Founded: | 2014 | Country: | Denmark |
| Employees: | N/A | City: | COPENHAGEN |
| Market Cap: | 77.7M | IPO Year: | 2021 |
| Target Price: | $8.67 | AVG Volume (30 days): | 323.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.42 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.80 - $2.10 | Next Earning Date: | 08-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of IO Biotech Inc. (IOBT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Novo Holdings A/S | IOBT | 10% Owner | Jul 25 '24 | Sell | $1.32 | 75,000 | $99,125.48 | 4,377,927 |
Latest IO Biotech Inc. News
IOBT Breaking Stock News: Dive into IOBT Ticker-Specific Updates for Smart Investing
Clinical Trials Arena
7 days ago
IO Biotech’s melanoma treatment trial to continue after IDMC review
MT Newswires
10 days ago
IO Biotech Gets Data Monitoring Committee Recommendation to Continue Phase 3 Melanoma Study
GlobeNewswire
10 days ago
IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma
GlobeNewswire
14 days ago
IO Biotech Announces Participation in Upcoming Investor Conferences
GlobeNewswire
a month ago
IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights
GlobeNewswire
a month ago
IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024
Simply Wall St.
2 months ago
IO Biotech, Inc.'s (NASDAQ:IOBT) market cap touched US$104m last week, benefiting both private equity firms who own 59% as well as institutions
Simply Wall St.
3 months ago
Will IO Biotech (NASDAQ:IOBT) Spend Its Cash Wisely?
Compare IOBT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IOBT IO Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.